For these reasons we started our analysis with a profound specificity validation of the ARID1A antibody applied and performed a thorough, comprehensive IHC-based ARID1A expression analysis in a large cohort of urothelial bladder carcinomas including carcinoma in situ (CIS) cases. This evidence concerns the gene ARID1A and bladder transitional cell carcinoma.